[go: up one dir, main page]

NO990787D0 - N6 heterocyklisk substituerte adenosinderivater - Google Patents

N6 heterocyklisk substituerte adenosinderivater

Info

Publication number
NO990787D0
NO990787D0 NO990787A NO990787A NO990787D0 NO 990787 D0 NO990787 D0 NO 990787D0 NO 990787 A NO990787 A NO 990787A NO 990787 A NO990787 A NO 990787A NO 990787 D0 NO990787 D0 NO 990787D0
Authority
NO
Norway
Prior art keywords
heterocyclic substituted
adenosine derivatives
substituted adenosine
sub
substituted
Prior art date
Application number
NO990787A
Other languages
English (en)
Other versions
NO990787L (no
NO312679B1 (no
Inventor
Robert T Lum
Jurg R Pfister
Steven R Schow
Michael M Wick
Marek G Nelson
George F Schreiner
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO990787D0 publication Critical patent/NO990787D0/no
Publication of NO990787L publication Critical patent/NO990787L/no
Priority to NO20020758A priority Critical patent/NO322459B1/no
Priority to NO20020759A priority patent/NO20020759D0/no
Publication of NO312679B1 publication Critical patent/NO312679B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19990787A 1996-08-27 1999-02-19 N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat NO312679B1 (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08702234 US5789416B1 (en) 1996-08-27 1996-08-27 N6 mono heterocyclic substituted adenosine derivatives
PCT/US1997/014724 WO1998008855A2 (en) 1996-08-27 1997-08-20 N6 heterocyclic substituted adenosine derivatives

Publications (3)

Publication Number Publication Date
NO990787D0 true NO990787D0 (no) 1999-02-19
NO990787L NO990787L (no) 1999-02-19
NO312679B1 NO312679B1 (no) 2002-06-17

Family

ID=24820367

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19990787A NO312679B1 (no) 1996-08-27 1999-02-19 N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20020758A NO322459B1 (no) 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.
NO20020759A NO20020759D0 (no) 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater

Country Status (24)

Country Link
US (1) US5789416B1 (no)
EP (3) EP0920438B1 (no)
JP (1) JP3157842B2 (no)
KR (1) KR100331775B1 (no)
CN (1) CN100363377C (no)
AT (2) ATE234323T1 (no)
AU (1) AU726597B2 (no)
BR (1) BR9711444A (no)
CA (1) CA2264155C (no)
CZ (1) CZ296855B6 (no)
DE (2) DE69705312T2 (no)
DK (2) DK0992510T3 (no)
ES (2) ES2157593T3 (no)
GE (1) GEP20012419B (no)
GR (1) GR3036332T3 (no)
HU (1) HU226057B1 (no)
IL (2) IL128652A0 (no)
NO (3) NO312679B1 (no)
NZ (3) NZ505428A (no)
PL (1) PL187635B1 (no)
PT (1) PT920438E (no)
TR (2) TR199900377T2 (no)
UA (1) UA62936C2 (no)
WO (1) WO1998008855A2 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
AU774404C (en) * 1999-05-25 2005-06-30 Board Of Trustees Of The Leland Stanford Junior University DNA methyltransferase inhibitors
EP1420021A1 (en) * 1999-05-25 2004-05-19 The Penn State Research Foundation DNA Methyltransferase inhibitors
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6784165B1 (en) 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
WO2002020024A1 (en) * 2000-09-08 2002-03-14 Cv Therapeutics, Inc. Purine ribosides as antiarrhythmics
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20050227933A1 (en) * 2001-11-29 2005-10-13 Benkovic Stephen J Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
CN1325504C (zh) * 2002-01-10 2007-07-11 宾夕法尼亚州研究基金会 制备二芳基硼酸烷基酯和络合的二芳基硼酸的方法
NZ534801A (en) 2002-02-19 2006-04-28 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
CN101385738A (zh) * 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
WO2003097643A1 (en) 2002-05-17 2003-11-27 Neurogen Corporation Substituted ring-fused imidazole derivates: gabaa receptor ligands
KR20050097971A (ko) * 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ₁아데노신 수용체의 부분 및 전 작용제
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
MXPA05011428A (es) * 2003-04-24 2006-05-31 Aderis Pharmaceuticals Inc Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US6881851B1 (en) * 2004-04-21 2005-04-19 Eastman Chemical Company Preparation of tetrahydro-3-furoic acid
ME01072B (me) * 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
MX2007003271A (es) * 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
CN100451010C (zh) * 2004-12-21 2009-01-14 厦门大学 一种合成(r)-3-氨基四氢呋喃的方法
JP5042996B2 (ja) * 2005-05-19 2012-10-03 ギリアード・パロ・アルト・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
CN100344768C (zh) * 2005-11-24 2007-10-24 东华大学 一种3－(s)－氨基四氢呋喃的酶法合成方法
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
JP5697993B2 (ja) 2008-02-11 2015-04-08 アールエックスアイ ファーマシューティカルズ コーポレーション 修飾ＲＮＡｉポリヌクレオチドおよびその使用
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
JP2012502991A (ja) 2008-09-22 2012-02-02 アールエックスアイ ファーマシューティカルズ コーポレーション 皮膚適用におけるｒｎａ干渉
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2523669B1 (en) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
WO2011119969A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
JP2016513706A (ja) 2013-03-15 2016-05-16 イノテック ファーマシューティカルズ コーポレイション 点眼用製剤
WO2015084897A2 (en) 2013-12-02 2015-06-11 Mirimmune, Llc Immunotherapy of cancer
JP6883987B2 (ja) 2013-12-04 2021-06-09 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
US20170051290A1 (en) 2014-05-01 2017-02-23 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CA2991598A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
CN105218490B (zh) * 2015-11-10 2017-05-03 山东川成医药股份有限公司 一种（r）‑3‑氨基四氢呋喃的制备方法
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
JP2023501445A (ja) 2019-11-08 2023-01-18 フィオ ファーマシューティカルズ コーポレーション 免疫治療のためのブロモドメイン含有タンパク質４（ｂｒｄ４）を標的とする化学修飾されたオリゴヌクレオチド
WO2021138537A1 (en) 2019-12-31 2021-07-08 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
JP2024529025A (ja) 2021-08-04 2024-08-01 フィオ ファーマシューティカルズ コーポレーション 化学修飾されたオリゴヌクレオチド
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) * 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
AU577743B2 (en) * 1984-10-26 1988-09-29 Warner-Lambert Company N6-benzopyrano and benzothiopyrano adenosines
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
AU626983B2 (en) * 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) * 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer

Also Published As

Publication number Publication date
HK1020967A1 (en) 2000-05-26
BR9711444A (pt) 2000-01-18
DK0992510T3 (da) 2003-07-07
UA62936C2 (en) 2004-01-15
EP0920438B1 (en) 2001-06-20
EP0992510A1 (en) 2000-04-12
NZ512242A (en) 2004-01-30
CA2264155C (en) 2003-11-18
CN100363377C (zh) 2008-01-23
TR199900377T2 (xx) 1999-05-21
NO990787L (no) 1999-02-19
JP3157842B2 (ja) 2001-04-16
AU726597B2 (en) 2000-11-16
DE69719816T2 (de) 2003-12-18
NO20020758L (no) 1999-02-19
NO20020758D0 (no) 2002-02-15
NO20020759D0 (no) 2002-02-15
DE69719816D1 (de) 2003-04-17
PL187635B1 (pl) 2004-08-31
ES2189330T3 (es) 2003-07-01
NZ505428A (en) 2005-03-24
CN1234803A (zh) 1999-11-10
NO312679B1 (no) 2002-06-17
EP0992510B1 (en) 2003-03-12
CZ296855B6 (cs) 2006-07-12
EP1081155A2 (en) 2001-03-07
PT920438E (pt) 2001-10-30
PL331853A1 (en) 1999-08-16
DK0920438T3 (da) 2001-09-10
NO20020759L (no) 1999-02-19
IL128652A (en) 2008-06-05
HUP0001640A2 (hu) 2001-05-28
US5789416A (en) 1998-08-04
KR100331775B1 (ko) 2002-04-09
TR200202287T2 (tr) 2003-01-21
IL128652A0 (en) 2000-01-31
ES2157593T3 (es) 2001-08-16
CZ61499A3 (cs) 1999-10-13
NO322459B1 (no) 2006-10-09
JP2000501426A (ja) 2000-02-08
EP0920438A2 (en) 1999-06-09
KR20000035867A (ko) 2000-06-26
HUP0001640A3 (en) 2002-04-29
CA2264155A1 (en) 1998-03-05
ATE234323T1 (de) 2003-03-15
WO1998008855A2 (en) 1998-03-05
ATE202361T1 (de) 2001-07-15
NZ334095A (en) 2000-10-27
GEP20012419B (en) 2001-04-25
AU4080997A (en) 1998-03-19
GR3036332T3 (en) 2001-11-30
DE69705312D1 (de) 2001-07-26
US5789416B1 (en) 1999-10-05
DE69705312T2 (de) 2001-10-11
WO1998008855A3 (en) 1998-09-03
EP1081155A3 (en) 2003-05-02
HU226057B1 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
US5789416B1 (en) N6 mono heterocyclic substituted adenosine derivatives
BR9711262A (pt) Derivados 6,6 substituido hetero biciclicos
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
ATE340176T1 (de) Substituierte 6,5-heterobicyclische-derivate
AU2720199A (en) Five-membered, benzo-condensed heterocycles used as antithrombotic agents
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
FI914163L (fi) Heterocykliska derivat.
DE59501802D1 (de) Substituierte 1H-3-Aryl-pyrrolidin-2,4-dion-Derivate
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
ATE231847T1 (de) Substituierte 1,2,3,4- tetrahydronaphthalinderivate
PT843679E (pt) Derivados da1-(piperidinil 1,2-disubstituido)-(4-imidazole fundido)-piperidina
ATE212635T1 (de) 1,3,8-triazaspiro(4,5)decan-4-on-derivate
NO904901D0 (no) N-substituerte derivater av 3r,4r-etyl-((1-metyl-1h-imidazol-5-yl)metyl) -2-pyrrolidinon.
ATE250607T1 (de) 5h pyrrolo(2,1-c)(1,4)benzodiazepin-3- carboxamidderivate
ATE220674T1 (de) 12h-dibenzo(d,g)(1,3)dioxocin derivate
TR199802607A3 (tr) Alkil-veya benzil türevlerinin alkillenmesine yönelik usul.
DE69710921D1 (de) Heterocyclische substituierte pyrrolidinamid-derivate
FI970092A7 (fi) Pyrido(3,2,1-i,j)(3,1)bentsoksatsiinijohdannaiset
BR9609310A (pt) Derivados de 1,3-OXA(TIA)ZINA
PT796843E (pt) Derivados de 1,25-di-hidroxi-16,22,23-trisde-hidro-colecalciferol
FR2730489B1 (fr) Derives de 1-(2-(vinyl-substitues))-5h-2,3-benzodiazepine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees